| Literature DB >> 33917126 |
Tiziana Bachetti1,2, Francesca Rosamilia3, Martina Bartolucci4, Giuseppe Santamaria2, Manuela Mosconi5, Serenella Sartori6, Maria Rosaria De Filippo6, Marco Di Duca7, Valentina Obino1, Stefano Avanzini8, Domenico Mavilio9,10, Simona Candiani1, Andrea Petretto4, Alessio Pini Prato11, Isabella Ceccherini2, Francesca Lantieri3.
Abstract
Hirschsprung (HSCR) Associated Enterocolitis (HAEC) is a common life-threatening complication in HSCR. HAEC is suggested to be due to a loss of gut homeostasis caused by impairment of immune system, barrier defense, and microbiome, likely related to genetic causes. No gene has been claimed to contribute to HAEC occurrence, yet. Genetic investigation of HAEC by Whole-Exome Sequencing (WES) on 24 HSCR patients affected (HAEC) or not affected (HSCR-only) by enterocolitis and replication of results on a larger panel of patients allowed the identification of the HAEC susceptibility variant p.H187Q in the Oncostatin-M receptor (OSMR) gene (14.6% in HAEC and 5.1% in HSCR-only, p = 0.0024). Proteomic analysis on the lymphoblastoid cell lines from one HAEC patient homozygote for this variant and one HAEC patient not carrying the variant revealed two well distinct clusters of proteins significantly up or downregulated upon OSM stimulation. A marked enrichment in immune response pathways (q < 0.0001) was shown in the HAEC H187 cell line, while proteins upregulated in the HAEC Q187 lymphoblasts sustained pathways likely involved in pathogen infection and inflammation. In conclusion, OSMR p.H187Q is an HAEC susceptibility variant and perturbates the downstream signaling cascade necessary for the gut immune response and homeostasis maintenance.Entities:
Keywords: Hirschsprung Associated Enterocolitis (HAEC); Oncostatin-M receptor (OSMR); Whole-Exome Sequencing (WES); gut inflammation; mucosal immunity; proteomics
Mesh:
Substances:
Year: 2021 PMID: 33917126 PMCID: PMC8067804 DOI: 10.3390/ijms22083831
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Variants that ranked at the top after Next Generation Sequencing (NGS) filtering and prioritization.
| NGS | Replicate | Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rank | Chromosomal Position | Gene | AA | rs# | REF/ALT | gnomAD ° | MAF | MAF | Genotypes (omo/HT/wt) | MAF | ||||
|
|
|
|
|
|
|
| ||||||||
| 1 | chr19:17940842 |
| p.Ala1094Ala | rs3212780 | G/A | 0.281 | 0.375 | 0.250 | 0.321 | 3/14/17 | 3/21/30 | 0.294 | 0.250 | 0.6002 |
| 2 | chr21:48069682 |
| p.Arg229Trp | rs76937225 § | C/T | 0.039 | 0.292 | - | - | - | - | - | - | - |
| 3–4 | chr5:38884071 |
| p.His187Gln | rs34675408 | T/G | 0.070 | 0.292 | 0.117 | 0.057 | 2/17/53 | 0/11/97 | 0.146 | 0.051 |
|
| 3–4 | chr2:209190632 |
| p.Ser1033Ala | rs999890 | T/G | 0.140 | 0.292 | 0.150 | 0.143 | 2/9/21 | 0/6/27 | 0.203 | 0.091 | 0.0850 |
| 5–6 | chr11:7059981 |
| p.Arg55Gln | rs61063081 | G/A | 0.207 | 0.333 | 0.206 | 0.268 | 1/13/15 | 5/12/36 | 0.259 | 0.208 | 0.5581 |
| 5–6 | chr11:7091569 |
| p.Leu1010Phe | rs17280682 § | C/T | 0.207 | 0.333 | - | - | - | - | - | - | - |
° Non Finnish European controls; ^ Minor allele frequency (MAF) in controls was 0 for all the selected variants; * Fisher’s exact test p-values on NGS + replicate data; significant p-values (p < 0.05) are in italics; § rs76937225 (PRMT2) was not confirmed in one patients, rs17280682 (NLRP14) was not validated because in complete linkage disequilibrium (LD) with the selected variant rs61063081.
Family-based association performed on the Oncostatin-M receptor (OSMR) Single Nucleotide Polymorphism (SNP) rs34675408 using the Transmission Disequilibrium Test (TDT) on Hirschsprung (HSCR) Associated Enterocolitis (HAEC) and HSCR-only available trios.
|
| |||||||
|
|
|
|
|
|
|
|
|
|
| rs34675408 | T | G | 11:2 | 5.5 (1.2–24.8) | 6.231 | 0.0126 |
|
| |||||||
|
| rs34675408 | T | G | 2:5 | 0.4 (0.1–2.1) | 1.286 | 0.257 |
* Transmitted (T) and Untransmitted (U) ratio.
Figure 1OSMR secondary and tertiary structure. (a) The OSMR extracellular, transmembrane, and intracellular domains are shown, as well as the protein AA sequence, as obtained with Protter. The post translational modifications (PTMs) and known variants are also detailed, including the p.H187Q SNP, indicated by an arrow; (b) the 3D prediction of the OSMR protein structure was obtained by the Swiss Model server using a homology method. The whole protein model is shown on the left, while the region around H187 is enlarged in the right, distinguishing between the wt (above) and the p.H187Q variant sequence (below). The region is further zoomed in to show the three hotspots sites around H187 reported by Du et al. [19] in yellow, blue, and red, respectively, with the Tyr214 residue being the hot spot binding residue in common between the three.
Figure 2Perinuclear inclusions in H187 (LY3828) and p.H187Q homozygous variant (LY4759). (a) The amount of perinuclear formations are represented as means and standard deviations of the percentage of cells with inclusions obtained by three independent experimental session replicates. The inclusions percentage is higher in the p.H187Q homozygous HAEC LY4759 cell line than in the LY3828 cell line. The amount of inclusions is significantly increased by OSM treatment in LY4759 cells only. Statistical differences are indicated by an asterisk (* p < 0.0001); (b) immunofluorescence images of the OSM treated LY3828 and LY4759. Almost all the LY4759 cells showed round formations with the same localization as anti-Vim. The merge between pERK and vimentin is also displayed. The scale bar is 20 µm.
Figure 3pERK localized in the same compartment with RAB11. Fluorescence images show the same cellular compartment localization of pERK with RAB11 after the OSM treatments on LY4759 cells. Two examples are reported in the two columns. The perinuclear structures in which pERK and RAB11 cluster in ERC formations are visible. The scale bar is 20 µm.
Figure 4Protein cluster analysis. Cluster analysis of proteins differently expressed between the OSMR H187 patient’s cell line (LY3828, four replicates) and the p.H187Q homozygous patient’s cell line (LY4759, in triplicate) after OSM stimulation is shown. The two samples are referred to as wt+ and var+, respectively. (a) The Venn diagram represents the 458 proteins differently expressed between the wt and the var cell lines after OSM treatment (indicated by the “plus sign”) that were not significantly different between wt and var before treatment (“minus sign”); (b) the hierarchical analysis showed two clusters clearly visible in the heatmap for these 458 proteins: 187 proteins were overexpressed in var+ compared to wt+ (in blu in the heatmap color-scale), while 271 proteins were overexpressed in wt+ compared to var+ (in green).
Figure 5Pathway analysis in H187 (LY3828) and p.H187Q homozygous variant (LY4759) cells. The screenshot of the pathway analysis performed with HumanBase on the clusters of proteins obtained by Nano-LC mass spectrometry is shown. The 5 modules of pathways enriched based on the cluster of protein overexpressed in wt+ with respect to var+ are on the left, while the 7 enriched pathway modules in the cluster of protein overexpressed in var+ with respect to wt+ are on the right.